

AMENDMENT


In the Claims:

Please cancel claims 10-14 without prejudice or waiver.

Please enter new claims 19-25 as follows.

This listing of claims will replace all prior versions and listings of claims in the application.

Claim 1. (Original) A compound of Formula (I):



or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

A is -C(O)NHOH, -C(O)NHOR⁵, -C(O)NHOR⁶, -N(OH)COR⁵, or -N(OH)CHO;

U is absent or is O, NR^{a1}, C(O), CR^a(OH), C(O)O, OC(O), C(O)NR^{a1}, NR^{a1}C(O), OC(O)O, OC(O)NR^{a1}, NR^{a1}C(O)O, NR^{a1}C(O)NR^{a1}, S(O)_p, S(O)_pNR^{a1}, NR^{a1}S(O)_p, or NR^{a1}SO₂NR^{a1};

X is absent or is C₁₋₁₀ alkylene, C₂₋₁₀ alkenylene, or C₂₋₁₀ alkynylene;

Y is absent or is O, NR^{a1}, S(O)_p, or C(O);

provided that U-X-Y form a linker of at least two atoms between Z and Z^a and is other than OC(O) or OC(O)alkylene;

Z is phenyl substituted with 0-1 R^b, naphthyl substituted with 0-1 R^b, pyridyl substituted with 0-1 R^b, or pyrimidyl substituted with 0-1 R^b;

Z^a is a C₃₋₁₃ carbocycle substituted with 1-5 R^c or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)_p, and substituted with 1-5 R^c, provided that if Z^a is bicyclic, it does not contain a bridging nitrogen atom;

provided that U, Y, Z, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p, or S(O)_p-S(O)_p group;

R^1 is Q, C_{1-6} alkylene-Q, C_{2-6} alkenylene-Q, C_{2-6} alkynylene-Q,
- $(CR^aR^{al})_rO(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rNR^a(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rC(O)(CR^aR^{al})_s-Q$,
- $(CR^aR^{al})_rC(O)O(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rOC(O)(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rC(O)NR^aR^{al}$,
- $(CR^aR^{al})_rC(O)NR^a(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rNR^aC(O)(CR^aR^{al})_s-Q$,
- $(CR^aR^{al})_rOC(O)O(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rOC(O)NR^a(CR^aR^{al})_s-Q$,
- $(CR^aR^{al})_rNR^aC(O)O(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rNR^aC(O)NR^a(CR^aR^{al})_s-Q$,
- $(CR^aR^{al})_rS(O)_p(CR^aR^{al})_s-Q$, - $(CR^aR^{al})_rSO_2NR^a(CR^aR^{al})_s-Q$,
- $(CR^aR^{al})_rNR^aSO_2(CR^aR^{al})_s-Q$, or $(CR^aR^{al})_rNR^aSO_2NR^a(CR^aR^{al})_s-Q$;

R^2 is Q^1 , C_{1-6} alkylene- Q^1 , C_{2-6} alkenylene- Q^1 , C_{2-6} alkynylene- Q^1 ,
- $(CR^aR^{al})_rO(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rNR^a(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rC(O)(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rC(O)O(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rOC(O)(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rC(O)NR^aR^{al}$, - $(CR^aR^{al})_rC(O)NR^a(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rNR^aC(O)(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rOC(O)O(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rOC(O)NR^a(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rNR^aC(O)NR^a(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rS(O)_p(CR^aR^{al})_s-Q^1$, - $(CR^aR^{al})_rSO_2NR^a(CR^aR^{al})_s-Q^1$,
- $(CR^aR^{al})_rNR^aSO_2(CR^aR^{al})_s-Q^1$, or - $(CR^aR^{al})_rNR^aSO_2NR^a(CR^aR^{al})_s-Q^1$;

provided that when n is 0 and CR^1R^2 is $CHNH_2$, then Z^a is other than unsubstituted phenyl;

Q is, independently at each occurrence, H, CHF_2 , CH_2F , CF_3 , a C_{3-13} carbocycle substituted with 0-5 R^d , or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 0-5 R^d ;

Q^1 is, independently at each occurrence, H, a C_{3-13} carbocycle substituted with 0-5 R^d , or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 0-5 R^d ;

alternatively, R^1 and R^2 , when attached to the same carbon atom, combine to form a 3-7 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-2 R^d ;

alternatively, when two R^1 groups are present they and the two carbon atoms to which they are attached combine to form a 4-7 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-2 R^d , provided that when R^1 s combine to form a ring Z is other than naphthylene;

R^3 is H or C_{1-6} alkyl;

R^4 is H, C_{1-6} alkyl, phenyl, or benzyl;

provided that when R^4 is other than H and n is 0, then one or both of R^1 and R^2 are other than H;

alternatively, R^3 and R^4 together with the carbon and oxygen atoms to which they are attached form a 5-6 membered ring consisting of, in addition to the carbon and oxygen atom shown, carbon atoms and 0-1 ring double bonds and substituted with 0-2 R^c ;

R^a is, independently at each occurrence, H, C_{1-6} alkyl, phenyl, or benzyl;

R^{a1} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-1 R^{c1} , C_{2-6} alkenyl substituted with 0-1 R^{c1} , C_{2-6} alkynyl substituted with 0-1 R^{c1} , or $-(CH_2)_r$ -3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR^{a2} , O, and $S(O)_p$, and substituted with 0-3 R^{c1} ;

alternatively, R^a and R^{a1} when attached to a nitrogen, together with the nitrogen to which they are attached, combine to form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N, NR^{a2} , O, and $S(O)_p$;

R^{a2} is, independently at each occurrence, C_{1-4} alkyl, phenyl, or benzyl;

R^{a3} is, independently at each occurrence, H, C_{1-6} alkyl substituted with 0-1 R^{c1} , C_{2-6} alkenyl substituted with 0-1 R^{c1} , C_{2-6} alkynyl substituted with 0-1 R^{c1} , or $-(CH_2)_r$ -3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR^{a2} , O, and $S(O)_p$, and substituted with 0-3 R^{c1} ;

R^b is, independently at each occurrence, C_{1-6} alkyl substituted with 0-1 R^{c1} , OR^a , SR^a , Cl, F, Br, I, =O, CN, NO_2 , $-NR^{a1}$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^{a1}$, $-C(S)NR^{a1}$, $-NR^aC(O)NR^{a1}$, $-OC(O)NR^{a1}$, $-NR^aC(O)OR^a$, $-S(O)_2NR^{a1}$,

$-\text{NR}^{\text{a}}\text{S}(\text{O})_2\text{Ra}^3$, $-\text{NR}^{\text{a}}\text{S}(\text{O})_2\text{NR}^{\text{a}}\text{Ra}^1$, $-\text{OS}(\text{O})_2\text{NR}^{\text{a}}\text{Ra}^1$, $-\text{S}(\text{O})_{\text{p}}\text{Ra}^3$, CF_3 , CF_2CF_3 , CHF_2 , CH_2F , or phenyl;

R^{c} is, independently at each occurrence, H, OR^{a} , Cl, F, Br, I, $=\text{O}$, CN, NO_2 , CF_3 , $-\text{CF}_2\text{CF}_3$, CH_2F , CHF_2 , $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(=\text{NCN})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(=\text{NR}^{\text{a}})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(=\text{NOR}^{\text{a}})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{O})\text{NR}^{\text{a}}\text{OH}$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{O})\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{O})\text{OR}^{\text{a}}$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{S})\text{OR}^{\text{a}}$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{C}(\text{O})\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}(\text{S})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{OC}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{C}(\text{O})\text{OR}^{\text{a}}$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{C}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{S}(\text{O})_{\text{p}}\text{Ra}^3$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{SO}_2\text{NR}^{\text{a}}\text{Ra}^1$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{SO}_2\text{Ra}^3$, $-(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{NR}^{\text{a}}\text{SO}_2\text{NR}^{\text{a}}\text{Ra}^1$, C_{1-6} alkyl substituted with 0-2 $\text{R}^{\text{c}1}$, C_{2-6} alkenyl substituted with 0-2 $\text{R}^{\text{c}1}$, C_{2-6} alkynyl substituted with 0-2 $\text{R}^{\text{c}1}$, $(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{C}_{3-10}$ carbocycle substituted with 0-2 $\text{R}^{\text{c}1}$, or $(\text{CR}^{\text{a}}\text{Ra}^1)_r\text{5-14}$ membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $\text{S}(\text{O})_{\text{p}}$, and substituted with 0-2 $\text{R}^{\text{c}1}$;

alternatively, when two R^{c} groups are attached to the same carbon atom, they form a 3-8 membered carbocyclic or heterocyclic spiro ring C substituted with 0-2 $\text{R}^{\text{c}1}$ and consisting of carbon atoms, 0-4 ring heteroatoms selected from O, N, and $\text{S}(\text{O})_{\text{p}}$, and 0-2 double bonds, provided that ring C contains other than a S-S, O-O, or S-O bond;

alternatively, when two R^{c} groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or heterocyclic ring D substituted with 0-2 $\text{R}^{\text{c}1}$ and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and $\text{S}(\text{O})_{\text{p}}$;

$\text{R}^{\text{c}1}$ is, independently at each occurrence, H, C_{1-4} alkyl, OR^{a} , Cl, F, Br, I, $=\text{O}$, CF_3 , CN, NO_2 , $-\text{C}(\text{O})\text{Ra}^{\text{a}}$, $-\text{C}(\text{O})\text{OR}^{\text{a}}$, $-\text{C}(\text{O})\text{NR}^{\text{a}}\text{Ra}^{\text{a}}$, or $-\text{S}(\text{O})_{\text{p}}\text{Ra}^{\text{a}}$;

R^{d} is, independently at each occurrence, C_{1-6} alkyl, OR^{a} , Cl, F, Br, I, $=\text{O}$, CN, NO_2 , $\text{NR}^{\text{a}}\text{Ra}^1$, $\text{C}(\text{O})\text{Ra}^{\text{a}}$, $\text{C}(\text{O})\text{OR}^{\text{a}}$, $\text{C}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $\text{C}(\text{S})\text{NR}^{\text{a}}\text{Ra}^1$, $\text{Ra}^{\text{a}}\text{NC}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $\text{OC}(\text{O})\text{NR}^{\text{a}}\text{Ra}^1$, $\text{Ra}^{\text{a}}\text{NC}(\text{O})\text{O}$, $\text{S}(\text{O})_2\text{NR}^{\text{a}}\text{Ra}^1$, $\text{NR}^{\text{a}}\text{S}(\text{O})_2\text{Ra}^3$, $\text{NR}^{\text{a}}\text{S}(\text{O})_2\text{NR}^{\text{a}}\text{Ra}^1$, $\text{OS}(\text{O})_2\text{NR}^{\text{a}}\text{Ra}^1$, $\text{S}(\text{O})_{\text{p}}\text{Ra}^3$, CF_3 , CF_2CF_3 , C_{3-10} carbocycle, or a 5-14 membered

heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)_p;

R⁵ is, independently at each occurrence, C₁₋₁₀ alkyl substituted with 0-2 R^b, or C₁₋₈ alkyl substituted with 0-2 R^e;

R^e is, independently at each occurrence, phenyl substituted with 0-2 R^b, or biphenyl substituted with 0-2 R^b;

R⁶ is, independently at each occurrence, phenyl, naphthyl, C₁₋₁₀ alkyl-phenyl-C₁₋₆ alkyl-, C₃₋₁₁ cycloalkyl, C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxycarbonyloxy-C₁₋₃ alkyl-, C₂₋₁₀ alkoxycarbonyl, C₃₋₆ cycloalkylcarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxycarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy-C₁₋₃ alkyl-, phenylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy-C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, [5-(C₁-C₅ alkyl)-1,3-dioxo-cyclopenten-2-one-yl]methyl, [5-(R^a)-1,3-dioxo-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyl, -C₁₋₁₀ alkyl-NR⁷R^{7a}, -CH(R⁸)OC(=O)R⁹, or -CH(R⁸)OC(=O)OR⁹;

R⁷ is H, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, or phenyl-C₁₋₆ alkyl-;

R^{7a} is H, C₁₋₁₀ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, or phenyl-C₁₋₆ alkyl-;

R⁸ is H or C₁₋₄ linear alkyl;

R⁹ is H, C₁₋₈ alkyl substituted with 1-2 R^f, C₃₋₈ cycloalkyl substituted with 1-2 R^f, or phenyl substituted with 0-2 R^b;

R^f is, independently at each occurrence, C₁₋₄ alkyl, C₃₋₈ cycloalkyl, C₁₋₅ alkoxy, or phenyl substituted with 0-2 R^b;

n is 0 or 1;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

s, at each occurrence, is selected from 0, 1, 2, 3, and 4;

provided that:

- (a) when R^4 , R^1 , and R^2 are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R^1 , R^2 , and R^4 is other than H.

Claim 2. (Original) A compound according to Claim 1, wherein:

U is absent or is O, NR^{a1} , $C(O)$, $CR^a(OH)$, $C(O)O$, $OC(O)$, $C(O)NR^{a1}$, $NR^{a1}C(O)$, $S(O)_p$, $S(O)_pNR^{a1}$, or $NR^{a1}S(O)_p$;

X is absent or is C_{1-3} alkylene or C_{3-4} alkynylene;

Y is absent or is O, NR^{a1} , $S(O)_p$, or $C(O)$;

provided that U-X-Y form a linker of at least two atoms between Z and Z^a and is other than $OC(O)$ or $OC(O)$ alkylene;

Z is phenyl substituted with 0-1 R^b , naphthyl substituted with 0-1 R^b , or pyridyl substituted with 0-1 R^b ;

Z^a is a C_{3-13} carbocycle substituted with 1-3 R^c or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 1-3 R^c , provided that if Z^a is bicyclic, it does not contain a bridging nitrogen atom;

provided that U, Y, Z, and Z^a do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, O- $S(O)_p$, or $S(O)_p$ - $S(O)_p$ group;

R^1 is Q, C_{1-6} alkylene-Q, C_{2-6} alkenylene-Q, C_{2-6} alkynylene-Q, $-(CR^aR^{a1})_rO(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rNR^a(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rC(O)(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rC(O)O(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rC(O)NR^aR^{a1}$, $-(CR^aR^{a1})_rC(O)NR^a(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rS(O)_p(CR^aR^{a1})_s-Q$, $-(CR^aR^{a1})_rSO_2NR^a(CR^aR^{a1})_s-Q$, or $-(CR^aR^{a1})_rNR^aSO_2(CR^aR^{a1})_s-Q$;

R^2 is Q^1 , C_{1-6} alkylene- Q^1 , C_{2-6} alkenylene- Q^1 , C_{2-6} alkynylene- Q^1 ,

$-(\text{CR}^a\text{R}^{a1})_r\text{O}(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$, $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{O}(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$, $-(\text{CR}^a\text{R}^{a1})_r\text{OC}(\text{O})(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{NR}^a\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{NR}^a(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{C}(\text{O})(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$, $-(\text{CR}^a\text{R}^{a1})_2\text{S}(\text{O})_p(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{SO}_2\text{NR}^a(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$, or $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{SO}_2(\text{CR}^a\text{R}^{a1})_s-\text{Q}^1$;

provided that when n is 0 and CR^1R^2 is CHNH_2 , then Z^a is other than unsubstituted phenyl;

Q is, independently at each occurrence, H , CHF_2 , CH_2F , CF_3 , a C_{3-13} carbocycle substituted with 0-3 R^d , or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N , O , and $\text{S}(\text{O})_p$, and substituted with 0-3 R^d ;

alternatively, R^1 and R^2 , when attached to the same carbon atom, combine to form a 5-6 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N , O , and $\text{S}(\text{O})_p$ and substituted with 0-2 R^d ;

R^a is, independently at each occurrence, H , C_{1-6} alkyl, phenyl, or benzyl;

R^{a1} is, independently at each occurrence, H , C_{1-6} alkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, or $-(\text{CH}_2)_{r-3-8}$ membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N , NR^{a2} , O , and $\text{S}(\text{O})_p$;

alternatively, R^a and R^{a1} when attached to a nitrogen, together with the nitrogen to which they are attached, combine to form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N , NR^{a2} , O , and $\text{S}(\text{O})_p$;

R^c is, independently at each occurrence, H , OR^a , Cl , F , Br , $=\text{O}$, CN , NO_2 , CF_3 , CH_2F , CHF_2 , CF_2CF_3 , $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{OR}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{NR}^a\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{C}(\text{O})\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{S}(\text{O})_p\text{R}^{a3}$, $-(\text{CR}^a\text{R}^{a1})_r\text{SO}_2\text{NR}^a\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{SO}_2\text{R}^{a3}$, C_{1-6} alkyl substituted with 0-1 R^{c1} , C_{2-6} alkenyl substituted with 0-1 R^{c1} , C_{2-6} alkynyl substituted with 0-1 R^{c1} ,

$-(CH_2)_r-C_{3-6}$ carbocycle substituted with 0-2 R^{c1} , or $-(CH_2)_r-5-6$ membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 0-2 R^{c1} ;

alternatively, when two R^c groups are attached to the same carbon atom, they form a 3-8 membered carbocyclic or heterocyclic spiro ring C substituted with 0-2 R^{c1} and consisting of carbon atoms, 0-4 ring heteroatoms selected from O, N, and $S(O)_p$, and 0-2 double bonds, provided that ring C contains other than a S-S, O-O, or S-O bond;

alternatively, when two R^c groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or heterocyclic ring D substituted with 0-2 R^{c1} and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and $S(O)_p$;

R^d is, independently at each occurrence, C_{1-6} alkyl, OR^a , Cl, F, Br, =O, CN, NO_2 , $-NR^aR^{a1}$, $-C(O)R^a$, $-C(O)OR^a$, $-C(O)NR^aR^{a1}$, $-S(O)_2NR^aR^{a1}$, $-NR^aS(O)_2R^{a3}$, $-S(O)_pR^{a3}$, CF_3 , C_{3-6} carbocycle, or a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$;

R^5 is, independently at each occurrence, C_{1-6} alkyl substituted with 0-2 R^b , or C_{1-4} alkyl substituted with 0-2 R^e ;

R^7 is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, or phenyl- C_{1-6} alkyl-;

R^{7a} is H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, or phenyl- C_{1-6} alkyl-;

R^9 is H, C_{1-6} alkyl substituted with 1-2 R^f , C_{3-6} cycloalkyl substituted with 1-2 R^f , or phenyl substituted with 0-2 R^b ; and

R^f is, independently at each occurrence, C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, or phenyl substituted with 0-2 R^b ;

provided that:

- (a) when R^4 , R^1 , and R^2 are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

- (b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R^1 , R^2 , and R^4 is other than H.

Claim 3. (Original) A compound according to Claim 2, wherein:

A is $-C(O)NHOH$ or $-N(OH)CHO$;

U is absent or is O, NR^{a1} , $C(O)$, $CR^a(OH)$, $C(O)NR^{a1}$, $NR^{a1}C(O)$, $S(O)_p$, $S(O)_pNR^{a1}$, or $NR^{a1}S(O)_p$;

X is absent or is methylene, ethylene, propynylene, or butynylene;

provided that U-X-Y form a linker of at least two atoms between Z and Z^a ;

Z^a is a C_{5-10} carbocycle substituted with 1-3 R^c , or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 1-3 R^c , provided that if Z^a is bicyclic, it does not contain a bridging nitrogen atom;

provided that U, Y, Z, and Z^a do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, O- $S(O)_p$, or $S(O)_p$ - $S(O)_p$ group;

R^1 is Q, C_{1-6} alkylene-Q, C_{2-6} alkenylene-Q, C_{2-6} alkynylene-Q, $-(CH_2)_rO(CH_2)_s-Q$, $-(CH_2)_rNR^a(CH_2)_s-Q$, $-(CH_2)_rC(O)(CH_2)_s-Q$, $-(CH_2)_rC(O)O(CH_2)_s-Q$, $-(CH_2)_rC(O)NR^aR^{a1}$, $-(CH_2)_rC(O)NR^a(CH_2)_s-Q$, $-(CH_2)_rNR^aC(O)(CH_2)_s-Q$, $-(CH_2)_rS(O)_p(CH_2)_s-Q$, $-(CH_2)_rSO_2NR^a(CH_2)_s-Q$, or $-(CH_2)_rNR^aSO_2(CH_2)_s-Q$;

R^2 is Q^1 , C_{1-6} alkylene- Q^1 , C_{2-6} alkenylene- Q^1 , C_{2-6} alkynylene- Q^1 , $-(CR^aR^{a1})_rO(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rNR^a(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rC(O)(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rC(O)O(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rC(O)NR^a(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rNR^aC(O)(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rS(O)_p(CR^aR^{a1})_s-Q^1$, $-(CR^aR^{a1})_rSO_2NR^a(CR^aR^{a1})_s-Q^1$, or $-(CR^aR^{a1})_rNR^aSO_2(CR^aR^{a1})_s-Q^1$;

provided that when n is 0 and CR^1R^2 is $CHNH_2$, then Z^a is other than unsubstituted phenyl;

Q is, independently at each occurrence, H, a C₃₋₈ carbocycle substituted with 0-3 R^d, or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)_p, and substituted with 0-3 R^d;

R^{a3} is, independently at each occurrence, H, C₁₋₆ alkyl, C₂₋₆ alkenyl, or -(CH₂)_r-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR^{a2}, O, and S(O)_p, and substituted with 0-3 R^{c1};

R^c is, independently at each occurrence, H, OR^a, Cl, F, Br, =O, CF₃, CH₂F, CHF₂, -(CR^aR^{a1})_rNR^aR^{a1}, -(CR^aR^{a1})_rC(O)R^{a1}, -(CR^aR^{a1})_rC(O)OR^{a1}, -(CR^aR^{a1})_rC(O)NR^aR^{a1}, -(CR^aR^{a1})_rNR^aC(O)R^{a1}, -(CR^aR^{a1})_rS(O)_pR^{a3}, -(CR^aR^{a1})_rSO₂NR^aR^{a1}, -(CR^aR^{a1})_rNR^aSO₂R^{a3}, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl substituted with 0-1 R^{c1}, phenyl substituted with 0-2 R^{c1}, or 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)_p, and substituted with 0-2 R^{c1};

alternatively, when two R^c groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or heterocyclic ring D substituted with 0-2 R^{c1} and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and S(O)_p;

R^d is, independently at each occurrence, C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -NR^aR^{a1}, -C(O)R^a, -C(O)OR^a, -C(O)NR^aR^{a1}, -S(O)₂NR^aR^{a1}, -NR^aS(O)₂R^{a3}, -S(O)_pR^{a3}, CF₃, or phenyl;

R⁵ is, independently at each occurrence, C₁₋₄ alkyl substituted with 0-2 R^b, or C₁₋₄ alkyl substituted with 0-2 R^e;

r, at each occurrence, is selected from 0, 1, 2, and 3; and

s, at each occurrence, is selected from 0, 1, 2, and 3;

provided that:

- (a) when R⁴, R¹, and R² are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

(b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R^1 , R^2 , and R^4 is other than H.

Claim 4. (Original) A compound according to Claim 3, wherein:

A is $-C(O)NHOH$;

U is absent or is O, NR^{a1} , $C(O)$, $CR^a(OH)$, $C(O)NR^{a1}$, $NR^{a1}C(O)$, $S(O)_pNR^{a1}$, or $NR^{a1}S(O)_p$;

Z is phenyl substituted with 0-1 R^b , or naphthyl substituted with 0-1 R^b ;

Z^a is phenyl substituted with 1-3 R^c , naphthyl substituted with 1-3 R^c , or a heterocycle substituted with 1-3 R^c and selected from furanyl, tetrahydrofuranyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, 4,5-dihydro-isoxazolyl, thienyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridoimidazolyl, pyrrolidinyl, pyrrolyl, indolyl, indolinyl, benzimidazolyl, benzothiazinyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydro-isoquinolinyl, indazolyl, isobenzofuranyl, isoindazolyl, isoindolinyl, isoindolyl, methylenedioxyphenyl, quinazolinyl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl, 1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-4-yl, 3,4-dihydro-2H-chomen-4-yl, 2H-chomen-4-yl, and pyrazolo[1,5-a]pyridinyl;

provided that U, Y, Z, and Z^a do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, O- $S(O)_p$, or $S(O)_p$ - $S(O)_p$ group;

Q^1 is, independently at each occurrence, H, a C_{3-10} carbocycle substituted with 0-5 R^d , or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 0-3 R^d ;

R^{a1} is, independently at each occurrence, H, C_{1-6} alkyl, phenyl, or benzyl;

R^{a3} is, independently at each occurrence, H, C_{1-6} alkyl, phenyl, or benzyl;

R^c is, independently at each occurrence, H, OR^a , Cl, F, Br, $=O$, CF_3 , CH_2F , CHF_2 ,

$-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{OR}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{NR}^a\text{R}^{a1}$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{C}(\text{O})\text{R}^{a1}$, $-(\text{CR}^a\text{R}^{a1})_r\text{S}(\text{O})_p\text{R}^{a3}$, $-(\text{CR}^a\text{R}^{a1})_r\text{SO}_2\text{NR}^a\text{R}^{a1}$,
 $-(\text{CR}^a\text{R}^{a1})_r\text{NR}^a\text{SO}_2\text{R}^{a3}$, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, phenyl substituted with
0-2 R^{c1}, or 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms
selected from N, O, and S(O)_p, and substituted with 0-2 R^{c1}; and

alternatively, when two R^c groups are attached to adjacent carbon atoms, together
with the carbon atoms to which they are attached they form a 5-6 membered carbocyclic
or heterocyclic ring D substituted with 0-2 R^{c1} and consisting of: carbon atoms and 0-2
heteroatoms selected from N, O, and S(O)_p;

provided that:

- (a) when R⁴, R¹, and R² are all H, then Z^a is other than a benzo-fused 5-6
membered heterocycle attached at the 2- or 3-position of the 5-6 membered
heterocycle; and
- (b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-
position of the 5-6 membered heterocycle, then at least one of R¹, R², and R⁴
is other than H.

Claim 5. (Original) A compound according to Claim 4, wherein:

U is absent or is O, NR^{a1}, C(O), CR^a(OH), C(O)NR^{a1}, or NR^{a1}C(O);

X is absent or is methylene or butynylene;

Y is absent or is O;

R² is Q¹, C₁₋₆ alkylene-Q¹, C₂₋₆ alkenylene-Q¹, C₂₋₆ alkynylene-Q¹,
 $-(\text{CH}_2)_r\text{O}(\text{CH}_2)_s\text{-Q}^1$, $-(\text{CH}_2)_r\text{NR}^a(\text{CH}_2)_s\text{-Q}^1$, $-(\text{CH}_2)_r\text{C}(\text{O})(\text{CH}_2)_s\text{-Q}^1$,
 $-(\text{CH}_2)_r\text{C}(\text{O})\text{O}(\text{CH}_2)_s\text{-Q}^1$, $-(\text{CH}_2)_r\text{C}(\text{O})\text{NR}^a(\text{CH}_2)_s\text{-Q}^1$, $-(\text{CH}_2)_r\text{NR}^a\text{C}(\text{O})(\text{CH}_2)_s\text{-Q}^1$,
 $-(\text{CH}_2)_r\text{S}(\text{O})_p(\text{CH}_2)_s\text{-Q}^1$, $-(\text{CH}_2)_r\text{SO}_2\text{NR}^a(\text{CH}_2)_s\text{-Q}^1$, or $-(\text{CH}_2)_r\text{NR}^a\text{SO}_2(\text{CH}_2)_s\text{-Q}^1$;

provided that when n is 0 and CR¹R² is CHNH₂, then Z^a is other than
unsubstituted phenyl;

Q is, independently at each occurrence, H, a C₃₋₆ carbocycle or a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)_p;

R^a is, independently at each occurrence, H, or C₁₋₄ alkyl;

R^{a1} is, independently at each occurrence, H, or C₁₋₄ alkyl;

R^{a3} is, independently at each occurrence, H, C₁₋₄ alkyl, phenyl, or benzyl;

R^c is, independently at each occurrence, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,

OR^a, Cl, F, Br, =O, CF₃, CH₂F, CHF₂, NR^aR^{a1}, -(CR^aR^{a1})_rC(O)R^{a1}, -
(CR^aR^{a1})_rC(O)OR^{a1},

-(CR^aR^{a1})_rC(O)NR^aR^{a1}, -(CR^aR^{a1})_rNR^aC(O)R^{a1}, -(CR^aR^{a1})_rS(O)_pR^{a3},

-(CR^aR^{a1})_rSO₂NR^aR^{a1}, -(CR^aR^{a1})_rNR^aSO₂R^{a3}, or phenyl; and

alternatively, when two R^c groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-6 membered carbocyclic or heterocyclic ring D substituted with 0-1 R^{c1} and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and S(O)_p;

provided that:

(a) when R⁴, R¹, and R² are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

(b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R¹, R², and R⁴ is other than H.

Claim 6. (Original) A compound according to Claim 5, wherein:

U is absent or is O, NR^{a1}, C(O), or CR^a(OH);

Y is absent;

R¹ is H or C₁₋₆ alkylene;

provided that when n is 0 and CR¹R² is CHNH₂, then Z^a is other than unsubstituted phenyl;

Q^1 is, independently at each occurrence, H, C_{3-6} cycloalkyl substituted with 0-1 R^d , phenyl substituted with 0-2 R^d , or a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and $S(O)_p$, and substituted with 0-2 R^d ;

r , at each occurrence, is selected from 0, 1, and 2; and

s , at each occurrence, is selected from 0, 1, and 2;

provided that:

- (a) when R^4 , R^1 , and R^2 are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R^1 , R^2 , and R^4 is other than H.

Claim 7. (Original) A compound according to Claim 6, wherein:

U is O, NR^{a1} , or $CR^a(OH)$;

Z^a is phenyl substituted with 1-3 R^c , naphthyl substituted with 1-3 R^c , or a heterocycle substituted with 1-3 R^c and selected from pyridyl, quinolinyl, imidazolyl, benzimidazolyl, indolyl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl, 1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-4-yl, 3,4-dihydro-2H-chomen-4-yl, 2H-chomen-4-yl, pyrazolyl, and pyrazolo[1,5-a]pyridinyl;

R^b is, independently at each occurrence, C_{1-6} alkyl, OR^a , Cl, F, Br, NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a1}$, $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a3}$, $S(O)_pR^{a3}$, or CF_3 ;

R^c is, independently at each occurrence, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, OR^a , Cl, F, Br, $=O$, NR^aR^{a1} , CF_3 , $-(CR^aR^{a1})_rC(O)R^{a1}$, $-(CR^aR^{a1})_rC(O)OR^{a1}$, $-(CR^aR^{a1})_rC(O)NR^aR^{a1}$, $-(CR^aR^{a1})_rNR^aC(O)R^{a1}$, $-(CR^aR^{a1})_rS(O)_pR^{a3}$, $-(CR^aR^{a1})_rSO_2NR^aR^{a1}$, or $(CR^aR^{a1})_rNR^aSO_2R^{a3}$; and

alternatively, when two R^c groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-6 membered saturated ring consisting of: carbon atoms and 0-1 heteroatoms selected from N, O, and $S(O)_p$;

provided that:

- (a) when R^4 , R^1 , and R^2 are all H, then Z^a is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when Z^a is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R^1 , R^2 , and R^4 is other than H.

Claim 8. (Original) A compound of Claim 1 selected from:

- 3,N-dihydroxy-2,2-dimethyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 3,N-dihydroxy-2-methyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 3,N-dihydroxy-2,2-dimethyl-3-[6-(2-methyl-quinolin-4-ylmethoxy)-naphthalen-2-yl]-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 4,N-dihydroxy-4-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-butyramide;
- 2-{hydroxy-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-methyl}-4-methyl-pentanoic acid hydroxyamide;
- 2-benzyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 2-furan-2-ylmethyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-(tetrahydrofuran-2-ylmethyl)-propionamide;
- 3,N-dihydroxy-2-(4-methoxy-benzyl)-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 2-(3,5-dimethoxy-benzyl)-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 2-benzo[1,3]dioxol-5-ylmethyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-4-ylmethyl-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-2-ylmethyl-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-3-ylmethyl-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-morpholin-4-ylmethyl-propionamide;

4-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-piperidine-1-carboxylic acid *tert*-butyl ester;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-piperidin-4-ylmethyl-propionamide;

4-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-piperazine-1-carboxylic acid *tert*-butyl ester;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-piperazin-1-ylmethyl-propionamide;

benzyl-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-carbamic acid *tert*-butyl ester;

2-(benzylamino-methyl)-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;

{2-hydroxy-1-hydroxycarbamoyl-2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-ethyl}-methyl-carbamic acid *tert*-butyl ester;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-(tetrahydro-pyran-4-yl)-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-butyramide;

N-hydroxy-2-{2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-tetrahydro-furan-2-yl}-acetamide; and

3,N-dihydroxy-3-(6-methoxy-naphthalen-2-yl)-2,2-dimethyl-propionamide;

or a stereoisomer or a pharmaceutically acceptable salt or prodrug form thereof.

Claim 9. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof.

Claim 10-18. (Canceled)

Claim 19. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or a pharmaceutically acceptable salt form thereof.

Claim 20. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or a pharmaceutically acceptable salt form thereof.

Claim 21. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or a pharmaceutically acceptable salt form thereof.

Claim 22. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or a pharmaceutically acceptable salt form thereof.

Claim 23. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or a pharmaceutically acceptable salt form thereof.

Claim 24. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 7 or a pharmaceutically acceptable salt form thereof.

Claim 25. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 8 or a pharmaceutically acceptable salt form thereof.